Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Gets Two Patents for Protein Profiling Technology

NEW YORK, June 26 - Ciphergen said today it has been awarded two patents for its SELDI protein profiling technology.

 

The patents include European Patent EP 0 700 521 B1, which covers the devices, methods, and instruments of SELDI, or Surface Enhanced Laser Desorption, technology, and US Patent 6,579,719, which covers protein expression profiling using chromatographic surfaces and detecting them with laser desorption mass spectrometry.

 

Ciphergen has exclusively licensed the first patent from Baylor College of Medicine, and is the sole owner of the US Patent.

 

"The European patent secures our rights to our core SELDI technology in Europe, and the U.S. patent supplements our basic U.S. patents with coverage for the most important ProteinChip technology application -- protein expression profiling -- which is at the heart of protein biomarker discovery," William Rich, President and CEO of Ciphergen, said in a statement.

The Scan

Cell Atlas of Human Lung Development Gives View of Developing Airway

Researchers have generated a cell atlas of human lung development, which they report in Cell.

Study Finds Costs of Genome Sequencing May Limit Utility in Routine Care

Researchers report in the European Journal of Human Genetics that genome sequencing for rare disease diagnoses currently has similar benefits as less expensive exome analysis.

Study Suggests Nursing Mother's Diet Can Impact Offspring's Gut Microbiome

A new Cell Host and Microbe paper finds that mice whose mothers were fed a low-fiber diet during nursing experience lasting microbiota dysbiosis and increased obesity.

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.